Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KDM6B | O15054 | 1/20 | 0.36 |
| ▸ | KDM5C | P41229 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.36 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29792056 | 1.00 | DGAT1 (0.43) | DGAT1ALDH1A1HIF1AARLCK | |
| SCHEMBL16065191 | 0.85 | UCHL1 (0.42) | DGAT1ALDH1A1HIF1AGSK3AGSK3B | |
| SCHEMBL2315142 | 0.84 | ALDH1A1 (0.40) | DGAT1ALDH1A1HIF1AGSK3AGSK3B | |
| SCHEMBL22685876 | 0.84 | ALDH1A1 (0.40) | DGAT1ALDH1A1HIF1AGSK3AGSK3B | |
| SCHEMBL29504593 | 0.84 | ALDH1A1 (0.40) | DGAT1ALDH1A1HIF1AGSK3AGSK3B | |
| SCHEMBL18274813 | 0.84 | KDM4E (0.46) | DGAT1ALDH1A1HIF1AGSK3AGSK3B | |
| SCHEMBL29514302 | 0.83 | KDR (0.39) | DGAT1HIF1AGSK3AGSK3BPDGFRB | |
| SCHEMBL14905026 | 0.83 | KDR (0.39) | DGAT1HIF1AGSK3AGSK3BPDGFRB | |
| SCHEMBL30939386 | 0.82 | F11 (0.40) | DGAT1HIF1AGSK3AGSK3BPDGFRB | |
| SCHEMBL17071940 | 0.82 | DGAT1 (0.40) | DGAT1ALDH1A1HIF1AGSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545662-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| WO-2025058977-A1 | MODULATORS OF CORONAVIRUS 3C-LIKE PROTEASE AND USES THEREOF | Vir Biotechnology, Inc. (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| EP-3617195-B1 | NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVES AS INHIBITORS OF TROPOMYOSIN RECEPTOR KINASE A FOR THE TREATMENT OF PAIN | MOCHIDA PHARM CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| US-11987574-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240140922-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2024-05-02 | — | — | US | disclosed |
| US-20240124428-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2024-04-18 | — | — | US | disclosed |
| WO-2024044183-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044183-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-4313970-A1 | MK2 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20120295883-A1 | COMPOUNDS | GENENTECH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| WO-2012038743-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-03-29 | — | — | WO | disclosed |
| EP-2366699-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-09-21 | — | — | EP | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | DGAT1 3787/4885ALDH1A1 530/4885HIF1A 1702/4885 |
| US-11987574-B2 | MK2 inhibitors and uses thereof | MKNK2, ENPP2, MAPKAPK2 | DGAT1 2022/4885ALDH1A1 4145/4885HIF1A 4328/4885 |
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | HAVCR2, HDGF, SLC10A1 | DGAT1 2725/4885ALDH1A1 3610/4885HIF1A 1138/4885 |
| US-20240140922-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | HAVCR2, HDGF, SLC10A1 | DGAT1 2605/4885ALDH1A1 3377/4885HIF1A 1264/4885 |
| US-20240124428-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | PCSK9, PCSK7, PCSK6 | DGAT1 539/4885ALDH1A1 3487/4885HIF1A 4662/4885 |
| US-20120295883-A1 | COMPOUNDS | ABCC5, PRNP, PC | DGAT1 3359/4885ALDH1A1 741/4885HIF1A 4368/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | DGAT1 2713/4885ALDH1A1 1380/4885HIF1A 1619/4885 |
| US-12545662-B2 | MK2 inhibitors and uses thereof | NR3C2, NR2C2, AGTR2 | DGAT1 985/4885ALDH1A1 3116/4885HIF1A 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.